Senti Biosciences, Inc. (NASDAQ:SNTI) Shares Acquired by ARK Investment Management LLC

ARK Investment Management LLC increased its position in Senti Biosciences, Inc. (NASDAQ:SNTI) by 7.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,969,860 shares of the company’s stock after acquiring an additional 143,785 shares during the period. ARK Investment Management LLC owned approximately 4.42% of Senti Biosciences worth $1,300,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in shares of Senti Biosciences in the 4th quarter worth approximately $25,000. Virtu Financial LLC acquired a new stake in shares of Senti Biosciences in the 2nd quarter worth approximately $43,000. Millennium Management LLC acquired a new stake in Senti Biosciences during the 2nd quarter valued at $71,000. TD Asset Management Inc grew its holdings in Senti Biosciences by 88.4% during the 3rd quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock valued at $102,000 after buying an additional 113,172 shares during the last quarter. Finally, Triatomic Management LP grew its holdings in Senti Biosciences by 42.5% during the 2nd quarter. Triatomic Management LP now owns 300,533 shares of the company’s stock valued at $188,000 after buying an additional 89,650 shares during the last quarter. Institutional investors and hedge funds own 25.73% of the company’s stock.

Senti Biosciences Trading Down 5.3 %

Shares of NASDAQ:SNTI opened at $0.39 on Thursday. The business’s fifty day moving average price is $0.42 and its two-hundred day moving average price is $0.43. Senti Biosciences, Inc. has a one year low of $0.27 and a one year high of $1.26.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter. Senti Biosciences had a negative net margin of 2,692.82% and a negative return on equity of 74.59%. As a group, sell-side analysts expect that Senti Biosciences, Inc. will post -1 earnings per share for the current fiscal year.

Senti Biosciences Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.